Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
25 April 2022 | Story Elsabé Brits
Andre Roodt and Alice Brink
Prof Andreas Roodt and Prof Alice Brink are two of the inventors of the ‘Multinuclear complexes and their preparation patent.

According to the World Health Organisation (WHO), cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six. The most common cancers are breast, lung, colon, rectum, and prostate cancers. There is a constant need to provide methods to diagnose and treat cancer-related tumours.  Current research strategies focus on eliminating cancer cells with the minimum damage to surrounding healthy cells.

A limitation of current technologies is that they are mostly based on the separate identification of cancer (diagnostic), followed by treatment (therapy) using chemotherapy and/or radiotherapy. To fit both needs at the same time and with similar or identical compounds, the principle of theranostic medicine was identified. This concept employs both diagnosing (by imaging) cancer and delivering therapy (treatment) simultaneously, which has been receiving increased attention internationally.

Collaborating with the University of Zurich
A University of the Free State (UFS) team, together with a team from the University of Zürich, conducted exciting research in this area and filed a patent titled ‘Multinuclear complexes and their preparation’. The patent was granted in South Africa and by the European Patent Office. It is being validated in selected European countries. The patent is pending in the USA, Japan, Hong Kong, and India. The inventors from the UFS are Prof Andreas Roodt, Prof Alice Brink, Dr Pennie Mokolokolo, and Dr Vincent Dumisani Kama. The approach that their technology takes is to enable the synthesis of a multinuclear compound/s, which may contain different pre-selected radioisotopes, to allow both imaging and therapy to the cancer site(s) with one and the same metal-organic complex.

So far, high-yield production of compounds has been successfully innovated, which contain both an imaging (in particular the widely utilised imaging isotope Technetium-99m) and therapeutic (typically the therapeutic isotope Rhenium-186) radioactive isotope(s), optionally carrying an additional cytotoxic agent. (Chemotherapy uses anti-cancer [cytotoxic] drugs to destroy cancer cells.)

Nuclear medicine technologies
In the next phase of the research, a lead compound portfolio of four to five model pharmaceuticals containing these metal nuclides with appropriate directing groups to target cancer sites will be designed and constructed. A number of these entities are known and can be introduced through different techniques. These will then undergo full characterisation and efficacy evaluation in biological models (in vitro), followed by extensive animal and human trials.

The technology will be delivered as a product or service in the way that current nuclear medicine technologies are delivered.

The fact that this product(s) contains both imaging and therapeutic radionuclides or cytotoxic modalities, enables detailed tracking of the pharmaceutical and monitoring of the tumours' response to the therapy. Not directly related to the patent, but an asset to it, is the fact that the incorporation of rhenium with a high atomic number (Z = 75) opens the additional opportunity to utilise the multinuclear compounds also as radiosensitisers. Synergistic effects, enhancing the therapeutic efficacy, can thus be expected in combination with radiotherapy.

The UFS would like to partner with a pharmaceutical company working in the field of nuclear medicine to commercialise this technology. Interested parties can contact Ravini Moodley at MoodleyR5@ufs.ac.za

News Archive

Inaugural lecture celebrates Qwaqwa founder, Morena Mopeli Mokhachane
2014-09-12

 

Photo: RooistoelTV

Every historical era presents its own challenges and creates its own leaders who take up the call to address those challenges.

This was expressed by Dr Nyefolo Malete who presented the Inaugural Memorial Lecture on 6 September 2014 at the Qwaqwa Campus. The lecture honoured the live of the Qwaqwa founder, Morena Paulus Mopeli Mokhachane.

Dr Malete said that Morena Mopeli played his part in history as a skilled negotiator, formidable team player and a liberator who held good human relations in high regard.

“Morena Mopeli lived at the time when Southern Africa was experiencing a moment of frustration and despair. It was faced with conflicts, battles, starvation and turmoil in preparation for a transformation that was to serve as the mirror of the political and social stage which existed until 1994,” Dr Malete said.

“He was a hopeful leader and thinker who played a critical role in assisting his brother Moshoeshoe to build and protect Lesotho where it was humanly possible. He participated in most of the negotiations with all the groups to create peace and protect the borders of Lesotho. He was a good, intelligent and formidable diplomat who was aware of his role as a leader. He was aware that he could influence the future through dialogue.”

Dr Malete said that Africa needs leaders like Mopeli. Leaders who can expand the capacity to remain open to possibilities and “envision a positive future in the face of uncertainty and to creatively construct pathways that can be embraced by all people who collectively seek to turn possibilities into reality.”

In attendance at the lecture were dignitaries from the Lesotho Royal House, the Free State Provincial Government and the Free State House of Traditional Leaders. 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept